Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,116.88
(
0.75%
)
US TECH 100
26,106.38
(
1.29%
)
Dow Jones
49,426.59
(
-0.04%
)
Brent Oil
97.15
(
2.25%
)
Bitcoin
78,950.37
(
3.44%
)
News Focus
News Focus
Post# of 257437
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122881
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 247696

Tuesday, 06/27/2023 4:02:01 PM

Tuesday, June 27, 2023 4:02:01 PM

Post# of 257437
VRTX addendum re islet-cell therapy:

VRTX has a second allogeneic cell therapy for T1D called VX-264, which is delivered as a surgical implant.

The stated advantage of VX-264 compared to VX-880 (the protagonist of the PR in #msg-172205380) is that VX-264 will not require immune-suppressing drugs because the implanted allogeneic islet cells will be encased in some kind of lattice that keeps immune cells at bay. That’s the theory, at least.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today